Late last week the Food and Drug Administration announced its approval of yet another drug to treat multiple sclerosis, this one touted as the only once-a-month, self-administered injection to treat relapsing forms of the disease.
But in light of the fact that Cambridge-based Biogen (Nasdaq: BIIB) already sells five other drugs for the disease (four of them in the U.S.), and this one is expected to only make a fraction of the revenues of company’s biggest-selling one, it’s fair to ask: Why bother?
